Seattle Genetics (SGEN) Announces FDA Granted Breakthrough Therapy Designation to ADCETRIS for Frontline Peripheral T-Cell Lymphomas
Tweet Send to a Friend
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
